Posted by Michael Wonder on 20 Aug 2025
Health Canada approves Ozempic to reduce the risk of sustained eGFR decline, end stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
19 August 2025 - Novo Nordisk announced today that Ozempic (semaglutide injection) is now approved as the first and only medication indicated for both the once weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control and to reduce the risk of sustained estimated glomerular filtration rate decline, end stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
Health Canada’s chronic kidney disease indication for Ozempic is based on the results of the FLOW trial.
